Bacteriophage-Resistant Staphylococcus aureus Mutant Confers Broad Immunity against Staphylococcal Infection in Mice by Capparelli, Rosanna et al.
Bacteriophage-Resistant Staphylococcus aureus Mutant
Confers Broad Immunity against Staphylococcal
Infection in Mice
Rosanna Capparelli
1, Nunzia Nocerino
1, Rosa Lanzetta
2, Alba Silipo
2, Angela Amoresano
2, Chiara
Giangrande
2, Karsten Becker
3, Giuseppe Blaiotta
4, Antonio Evidente
4, Alessio Cimmino
4, Marco
Iannaccone
1, Marianna Parlato
1, Chiara Medaglia
4, Sante Roperto
5, Franco Roperto
5, Luigi Ramunno
4,
Domenico Iannelli
4*
1Faculty of Biotechnology, University of Naples, Portici, Naples, Italy, 2Department of Organic Chemistry and Biochemistry, University of Naples, Naples, Italy,
3Universita ¨tsklinikum Mu ¨nster Institut fu ¨r Medizinische Mikrobiologie, Mu ¨nster, Germany, 4School of Agriculture, University of Naples, Portici, Naples, Italy, 5Department
of Pathology and Animal Health, University of Naples, Naples, Italy
Abstract
In the presence of a bacteriophage (a bacteria-attacking virus) resistance is clearly beneficial to the bacteria. As expected in
such conditions, resistant bacteria emerge rapidly. However, in the absence of the phage, resistant bacteria often display
reduced fitness, compared to their sensitive counterparts. The present study explored the fitness cost associated with
phage-resistance as an opportunity to isolate an attenuated strain of S. aureus. The phage-resistant strain A172 was isolated
from the phage-sensitive strain A170 in the presence of the M
Sa phage. Acquisition of phage-resistance altered several
properties of A172, causing reduced growth rate, under-expression of numerous genes and production of capsular
polysaccharide. In vivo, A172 modulated the transcription of the TNF-a, IFN-c and Il-1b genes and, given intramuscularly,
protected mice from a lethal dose of A170 (18/20). The heat-killed vaccine also afforded protection from heterologous
methicillin-resistant S. aureus (MRSA) (8/10 mice) or vancomycin-intermediate S. aureus (VISA) (9/10 mice). The same vaccine
was also effective when administered as an aerosol. Anti-A172 mouse antibodies, in the dose of 10 ml/mouse, protected the
animals (10/10, in two independent experiments) from a lethal dose of A170. Consisting predominantly of the sugars
glucose and galactose, the capsular polysaccharide of A172, given in the dose of 25 mg/mouse, also protected the mice (20/
20) from a lethal dose of A170. The above results demonstrate that selection for phage-resistance can facilitate bacterial
vaccine preparation.
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Introduction
Staphylococcus aureus can cause minor infections as well as life-
threatening diseases. Endocarditis, osteomyelitis, pneumonia,
surgical wound and intravascular device infections caused by S.
aureus represent a major public health concern [1–3]. In the United
States, about 60% of nosocomial S. aureus bloodstream infections
and 40–60% of surgical wound infections are caused by
methicillin-resistant strains of S. aureus (MRSA) [3]. One of these
MRSA strains has been reported to cause an alarming number of
necrotizing fasciitis cases [3]. Strains of S. aureus with reduced
susceptibility to vancomycin are also emerging [2,4]. In the wake
of the rising antimicrobial resistance [5], new strategies for the
control of S. aureus infections are needed. This study describes the
development of a vaccine active against S. aureus.
In the presence of an antibiotic or a bacteriophage (a bacteria-
attacking virus), resistance is clearly beneficial to the bacteria. As
might be expected, in such conditions, resistant bacteria are swift
to emerge [6]. However, in vivo and in vitro experiments
demonstrate that, in the absence of the antibiotic or phage,
resistant bacteria often display reduced fitness compared to their
sensitive counterparts [6–8]. This fitness cost is particularly high in
the case of phage-resistant bacterial strains. To infect bacteria,
phages often select an essential component of the bacterial cell wall
as a receptor [8]. To gain resistance, bacteria must dispose of this
component or alter its conformation [8]. However, this strategy is
costly to bacteria, which often become less virulent or avirulent.
The present study explored the cost of phage resistance to isolate
an attenuated strain of S. aureus. In a mouse model of infection, this
phage-resistant strain prevented infections from diverse and
clinically relevant S. aureus strains.
Materials and Methods
Bacteria
S. aureus strains A170, A177, A179 and A181 were isolated from
clinical samples collected from patients with infected surgical
wounds (one of the patients had diabetes; one wounds from a car
PLoS ONE | www.plosone.org 1 July 2010 | Volume 5 | Issue 7 | e11720incident; the remaining two were patients who underwent
abdominal surgery). Patients were hospitalized at the Medical
School of the University of Naples Federico II. Clinical samples
were streaked on trypticase soy agar (TSA) (Oxoid, Milan, Italy)
and single colonies expanded in trypticase soy broth (TSB)
(Oxoid). The strains listed above and their phage-resistant mutants
(A172, A178, A180, A182) were all identified as S. aureus [9]. For
in vivo and in vitro experiments, bacteria were grown in TSB at
37uC, harvested while in exponential growth phase (OD600: 1.5 to
1.8), centrifuged (8610
36g for 10 min) and washed with saline
(0.15 M NaCl). Serial 10-fold dilutions in saline were then plated
on TSA.
Mice
Experiments were carried out on female Balb/c mice (aged 8 to
10 weeks) at the animal facility of the University of Naples. Mice
were infected via the intramuscular or aerosol routes. In the case of
the intramuscular infection, mice received 5610
6–10
8 bacteria (as
detailed in each experiment) suspended in sterile saline (100 ml/
mouse). In the case of aerosol infection, mice were placed in a
nebulizing chamber and exposed to an aerosol solution (10
7 CFU/
ml) for 10 min. When inspected on the day of infection, the lungs
displayed about 1.6610
565.5610
3 CFU/g/mouse (average of 3
mice). Organs were dissected and weighed. Samples were
homogenized in 1 ml saline and serially diluted in saline. Colony
forming units (CFU) were evaluated by the plate count assay and
expressed as CFU/g. Animal experiments were approved by the
Animal Care Committee of the University of Naples (permit
number 86/609/EEC).
Isolation of the phage-resistant strains
Phage M
Sa was isolated from the S. aureus strain A170 following
induction with mitomycin [10]. Phages M
Sa1,M
Sa2 and M
Sa3 were
isolated from S. aureus strains A177, A179 and A181, respectively;
phage release was again induced with mitomycin [10]. Phage-
resistant S. aureus strains A172, A178, A180 and A182 were
isolated by plating dilutions of overnight susceptible cultures on
TSA containing increasing concentrations of the phage used for
selection. Ten single colonies growing at the highest phage
concentration were selected and subcultured twice on TSA agar in
the absence of phage. To ensure stability of resistance, two
colonies from each phage-resistant strain were further subcultured
(20 times or more) in the absence of phage. Induction of the
phage-resistant strains (including A172) with mitomycin excluded
the presence of prophages in these strains.
Titration of anti-A172 antibodies
Mice were immunized with the A172 strain (10
8 CFU/mouse)
and two weeks later sacrificed and the blood pooled. The protein
A gene is under-expressed in the A172 strain. Yet, to avoid
interference with the protein A possibly present on the bacterial
surface, the wells of a 96-well plate (Falcon, Milan) were coated
with the S. aureus protein A negative strain Wood 46 [11],
quenched with 3% bovine serum albumin (50 ml/well; 2 h),
washed with PBS, incubated with anti-A172 serum diluted (10
22–
10
24) in PBS (50 ml/well; 2 h), washed with PBS and incubated, in
succession, with peroxidase-labelled rat anti mouse IgG (50 ml/
well; 2h) and peroxidase substrate (100 ml/well; Bio-Rad, Milan).
Carbohydrate analysis
Teichoic acids from the A170 (A170
TA) and A172 (A172
TA)
isolates were prepared as described [12] and analyzed gas
chromatography-combined mass spectrometry. Monosaccharides
were identified as acetylated O-methyl glycosides derivatives, fatty
acids or O-methyl ester derivatives. After methanolysis with
methanolic HCl (2M HCl/CH3OH; 85uC, 24 h) and acetylation
with acetic anhydride in pyridine (85uC; 20 min), samples were
analyzed by gas chromatography-combined mass spectrometry
(GC-MS) and compared with standards. GC-MS analyses were
carried out on a Hewlett-Packard 5890 instrument using SPB-5
capillary column (0.2563 m; Supelco, PA). Ring size and
attachment points were determined by methylation analysis as
described [13]. The sample (1–2 mg) was methylated with CH3I/
NaOH in DMSO, hydrolysed with 2M trifluoroacetic acid (100uC,
for 4 h), reduced with NaBD4, acetylated with acetic anhydride in
pyridine and analyzed by GC-MS. The temperature programme
was: 150uC for 5 min and then 5uC/min to 300uC over 10 min.
Capsular polysaccharide purification
The A172 strain (100 ml) was grown in TSB. When in the
exponentialgrowthphase,the culturewascentrifuged(8610
66gfor
10 min) and the supernatant precipitated with ethanol (four
volumes) in the cold (220C overnight). Supernatant and precipitate
were separated by centrifugation (8610
66g for 10 min). The
precipitate, insoluble in H2O and several organic solvents
(methanol, ethanol, chloroform, or dimethyl sulfoxide), was
discarded. The supernatant was dialyzed (cut-off of the dialysis
tube: 3500 Daltons) against water (3 days), lyophilised, weighed and
tested for the capacity to protect mice. Mice vaccinated with the
supernatant (25 mg/mouse) were fully protected against a lethal
Figure 1. Pulsed field electrophoresis pattern of Sma I digests
from the Staphylococcus aureus A170 strain. The A172 strain (not
shown) displayed an identical pattern. M: DNA Size Standard, Lambda
Ladder (Concatemers of l cl857 Sam7) (Bio-Rad Laboratories, Hercules,
CA).
doi:10.1371/journal.pone.0011720.g001
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hydrolysed with 0.1 M HCl at 100uC for 48 h. The mixture was
neutralized with 2 M NaOH and reduced with sodiumborohydride
in distilled water (3 g/0.5 ml). The alditols were acetylated with
pyridine (100 ml) and acetic anhydride (100 ml) at 85uC for 30 min.
The monoses were identified as acetate alditols by gas liquid
chromatography (GLC) [14] using the Agilent GC-MS 7890A
instrument (Waghaeusel-Wiesental, Germany) equipped with a
capillary column (30 m60.25 mm, 0.25 mm film thickness) of SPB-
5 (Sigma Aldrich, Milan, Italy) and applying a temperature gradient
of 150uC (3 min) to 320uCa t3 uC/min.
Detection of A172 revertants
Individual wells of 96-well plates were filled with 200 ml TSB
medium and inoculated with one colony of A172 bacteria isolated
from mice vaccinated with the same strain and then grown in vitro
for 15 generations under stress conditions (10 mg/ml novobiocin)
[15]. Bacteria were grown for 3 h at 37uC. Individual cultures (10
9
CFU/200 ml) were quantitatively spread over a phage lawn (10
12
PFU/5 ml soft agar). Bacteria were thus surrounded by large
numbers of virus particles. Plates were inspected for the presence
of plaques of lysis during the next 4 days. The detection limit of the
test was established by carrying out the test on the same A172
cultures spiked with 12, 6, 3 or 1 A170 M
Sa-sensitive bacteria. The
dilutions with 12, 6, 3 or 1 A170 bacteria were assayed by plate
count in triplicate.
The presence of revertants was also investigated by an
independent method, based on the increase of phage titre of a
liquid culture upon addition of phage-sensitive bacteria [16]. A172
bacteria grown in the presence of novobiocin (10
9 CFU/200 ml)
were incubated for 1 h with the M
SA phage (10
5 PFU). The
cultures were then transferred quantitatively on a lawn of the A170
M
Sa-sensitive bacteria (10
5 CFU/4 ml soft agar) to determine
whether the original phage titre increased. The detection limit of
the test was established by testing in parallel the phage titre
increase that occurred in the same A172 cultures (10
9 CFU/
200 ml) spiked with 12, 6, 3 or 1 A170 M
Sa-sensitive bacteria. The
dilutions with 12, 6, 3 or 1 A170 bacteria were assayed as
described above.
Phage lysis inhibition
A170 or A172 bacteria (10
5 CFU/100 ml) were grown (4 h) in
2 ml TSB, in the presence or absence of: 5–20 mM N-acetyl-
glucosamine (GlcNAc), 5–20 mM glucose (Sigma, Milan), 0.1–
4 nmol/tube teichoic acid from A170 (A170
TA) or A172 (A172
TA).
The M
Sa phage (10
9 PFU7tube) was then added and bacterial
growth (OD600) measured 30 min later.
Phage inactivation by N-acetyl-glucosaminidase
A170 or A172 bacteria (10
5 CFU/100 ml) were grown (4 h) in
2 ml TSB, in the presence or absence of N-acetyl-glucosaminidase
from Canavalia ensiformis (Sigma; 4 U/tube). The M
Sa phage was
then added (10
9 PFU) and bacterial growth (OD600) measured
30 min later.
Pulsed-field electrophoresis of S. aureus strains
The procedure adopted was that described in [17]. Briefly,
inserts of intact DNA were digested in 200 ml of appropriate buffer
supplemented with 40 U of Sma I (Promega, Milan). Pulsed field
gel electrophoresis (PFGE) of the restriction digests was performed
by using the CHEF system (Bio-Rad Laboratories, Hercules, CA,
USA) with 1% (wt/vol) agarose gels and 0.56TBE as running
buffer, at 10uC. Restriction fragments were resolved in a single
run, at constant voltage of 6 V cm
2 and an orientation angle of
120u between electric fields, by a single phase procedure for 24 h
with a pulse ramping between 1 and 50s.
Other methods
The transcription level of bacterial virulence genes and mouse
cytokine genes was analyzed by real-time reverse transcription PCR
(RT-PCR) as described [18]. Fluorescein isothiocyanate labelled
A170 (A170
FITC) and A172 (A172
FITC) bacteria were prepared as
described [19]. Troponin was measured using the Mini Vidas
automated immunoassay analyzer and the Vidas troponin kit
(bioMereux, Florence, Italy). The sequence type of the S. aureus
strains were determined by sequencing the hypervariable region of
S. aureus protein A gene (spa) as described [20]. The spa types were
assigned using the Ridom spa-server (http://spaserver .de).
Multilocus sequence typing (MLST) of S. aureus strains was carried
out as described [21]. The bacterial genes eta, etb, tst, lukS-PV–lukF-
PV, lukE-lukD and lukM, (coding for the exfoliative toxin A,
exfoliative toxin B, toxic shock syndrome toxin1, Panton-Valentine
leukocidin components S and F, the leukotoxin LukELukD, and the
leukotoxin LukM, respectively) were detected by PCR [10]. The
staphylococcalenterotoxin (se)genesse-a,se-b, se-c, se-d,andse-ewere
detected as described [22]. The restriction endonucleases analysis-
enterotoxin gene cluster (REA-egc) type was carried out as described
[23]. Survival rates of mice were analyzed using Fisher’s exact test.
Bacterial counts and gene expression levels were analyzed using the
Figure 2. Differences between the phage M
Sa-sensitive strain A170 and the phage M
Sa-resistant strain A172. The strain A172 grows in
larger clumps (A) compared to the strain A170 (B). Bacteria were grown in liquid culture and collected for microscopic examination at the early
stationary phase. (C) The A172 strains displays also a slower growth rate, compared to A170.
doi:10.1371/journal.pone.0011720.g002
Figure 3. In S. aureus, phage-resistance comes with production
of capsular polysaccharide. (A) Strains A170, A177, A179, A181
(sensitive to the phages M
SA,M
SA1,M
Sa2,M
SA3, respectively). (B) Strains
A172, A178, A180, A182 (resistant to the phages M
SA,M
SA1,M
Sa2,M
SA3,
respectively).
doi:10.1371/journal.pone.0011720.g003
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.ridompaired t test (P values are two-tailed values). The molar
concentration of the teichoic acids from the S. aureus strains A170
and A172 were calculated attributing to A170 and A172 the
molecular weight of 6350 daltons (the average molecular weight of
the teichoic acid from S. aureus strain Copenhagen, which ranges
from 5400 to 7300 daltons) [24]
Results
Isolation and characterization of A172
The strains A170 and A172 were positive for the exfoliative toxin
B, the Panton-Valentine leukocidin, while negative for the
exfoliative toxin A, toxic shock syndrome toxin 1, the leukotoxin
LukELukD, the leukotoxin LukM and the staphylococcal entero-
toxins-a, -b,-c,-dand–e.ThestrainsA170 andA172 displayed also
the same egc type (egc-4), the multilocus sequence type (ST 45) and
spa-type (t6668) (spa-type repeats succession: 08-16-02-16-34-13-
17-34-34-34-34-34, equivalent to Kreiswirth’s IDs: XKAK-
BEMBBBBB). According to the Ridom    -server (http://
spaserver.ridom.de), t6668 represents a novel spa type. PFGE
analysis displayed a close genetic relation between the parental
phage M
Sa-sensitive strain A170 and the derivative phage-resistant
strain A172, as proved by the identical PFGE pattern of the Sma I
digests (Figure 1). A172 was isolated by growing the parental strain
A170 in the presence of increasing concentrations of the M
Sa phage
[10]. In addition to M
Sa, the strain A172 is also resistant to phages
M
Sa1,M
Sa2 and M
Sa3. Prolonged liquid subculture for several
months in the absence of phage or prolonged storage at 280uC did
not alter the resistance of A172 to M
Sa.
The strain was also highly stable in vivo. A172 bacteria were
isolated from a vaccinated mouse, grown for 15 generations under
stress conditions (10 mg/ml novobiocin) [15] and used to establish
400 independent bacterial cultures, which yielded a total number
of about 4610
11 bacteria (10
9, the number of cells/culture6400,
the number of cultures). Plated with phage in excess (10
12 PFU/
5 ml soft agar), the 400 independent bacterial cultures did not
yield any plaque of lysis. Control cultures (10
9 CFU A172/200 ml
spiked with 3 A170 bacteria), assayed in triplicate in three
independent experiments, displayed all at least one plaque and, on
average, 2.260.7 plaques/culture (number of replicas: 9). The
absence of A172 revertants was confirmed in a second indepen-
dent experiment. When the M
Sa phage (10
5 PFU) was mixed with
the A172 bacteria grown under stress conditions (10
9 CFU/
200 ml), no measurable increase in the phage titre occurred.
Control cultures (10
9 CFU A172/200 ml spiked with 3 A170
bacteria), compared to the non-spiked cultures, displayed an
increase in phage titre from 1.4610
5624610
3 to 1.2610
66
0.5610
3 (n: 9; P: 0.0057). Conservatively, it is estimated that A172
revertants occur at a frequency ,3610
29.
In liquid culture, compared to the parental strain, A172 formed
colonies with the tendency to clump together starting at the early
stationary phase (Figure 2A–B). Bacterial suspensions of A170 and
A172 with the same density (OD600: 0.6) were assayed by plate
count. In three independent experiments, A170 cultures contained
about 3 fold as many CFU as the A172 cultures (3.4610
76
6.7610
6 vs 1.2610
762.5610
6; P 0.003). A172 displayed reduced
growth rate during the exponential phase (Figure 2C) and reduced
doubling time (A172: 45 min62.8 min; A170: 3062.5 min; P
0.002). Also, unlike A170, A172 produced capsular polysaccharide
(Figure 3). Phage resistance altered the transcription of several
virulence factors. Among 14 ORFs of A172 analyzed, 13 were
significantly down-regulated compared to A170 (Figure 4). Down-
regulated ORFs comprise 9 genes, which control virulence factors
[25].
The receptor of the M
Sa phage is the N-
acetylglucosamine
Phages often use teichoic acids for adsorption on the cell wall of
Gram positive bacteria. They can use as receptor the glucose side
chains of Bacillus subtilis teichoic acids [26,27] or the N-
acetylglucosamine (GlcNAc) side chains of S. aureus [28]. To
identify the receptor site of the M
Sa phage, the A170 and A172
strains were grown in the presence or absence of 5–20 mM
GlcNAc or 5–20 mM glucose. GlcNAc inhibited the lysis of A170
by phage M
SA, while glucose did not. GlcNAc inhibition was dose-
dependent (Figure 5A–B). The experiment was repeated using the
teichoic acid from (A170
TA) or from (A172
TA) as inhibitor. Since
Figure 4. Expression levels of S. aureus A170 and A172 virulence factors. Acquisition of phage-resistance by A172 is accompanied by
extensive alterations in virulence gene expression levels. Out of the 14 ORFs examined, 13 are significantly under-expressed, compared to the phage-
sensitive strain A170. Bacteria were collected for transcriptional analysis during the exponential growth phase. SA0107 (spa, IgG binding protein A
precursor); SA0112 (hypothetical protein, similar to cysteine synthase); SA0184 (hypothetical protein); SA039 (geh; glycerol ester hydrolase); SA1007
(a-haemolysin); SA1160 (nuc; thermonuclease); SA1898 (hypothetical protein, similar to SceD precursor); SA2097 (hypothetical protein, similar to
secretory antigen precursor SsaA); SA2206 (sbi; IgG-binding protein SBI); SA2255 (oligopeptide transporter substrate binding protein); SA2406 (gbsA;
glycine betaine aldehyde dehydrogenase gbsA); SA2459 (ica; N-glycosyltransferase); SAR216 (groEL; chaperonin GROEL); SAR2117 (groES; co-
chaperonin GRES). ORFs numbers correspond to the S. aureus N315 genome sequence. Gene designations (when known) and proteins function are
shown in parentheses.
doi:10.1371/journal.pone.0011720.g004
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spathe quantity of teichoic acid that is isolated from the A170 or A172
strains varies significantly (2.4 mg from 10
10 CFU A170; 0.9 mg
from 10
10 CFU A172), the experiment was conducted using an
ample concentration range of the A170
TA and A172
TA reagents.
Under these conditions, phage inactivation occurred with A170
TA,
but not with A172
TA (Figure 5C). A170 bacteria were then treated
with N-acetylglucosaminidase (4 U/tube; 2 h at 37uC). Enzymatic
hydrolysis of GlcNAc from the A170 bacteria destroyed phage lysis
capacity (Figure 5D). Finally, analysis of teichoic acids from the
A170 (wild) and A172 (mutant) strains of S. aureus displayed the
absence of ribitol (Figure 6A) and terminal GlcNAc (t-GlcNAc)
residues (Figure 6B) from A172
TA. Collectively, the experiments
described above demonstrate that A172 conforms with the
tendency of several bacterial species - B. subtilis [26,27], S. aureus
[28], Salmonella enterica [18,29] - to acquire phage-resistance by
altering a cell wall polysaccharide component.
The A172 strain prevents S. aureus infection
For a more succinct presentation of the results, the distinctive
features of the experiments described in this and the following
sections are detailed in the Tables. One group of mice was
immunized with A172 live (A172-L) and two weeks later
infected with a lethal dose of A170. At the time of infection, in
the serum of immunized animals the titre of the antibodies
against A172-L ranged from 1:5000 to 1:12000. Control mice
were also infected with a lethal dose of A170. The A172-L
vaccine protected 90% of the mice (surviving mice: 18/20) from
A170, while the control mice (10/10) died within 4 days (P:
0.008; Table 1, experiment 1). When examined at the end of the
experiment (14 days after challenge), the kidneys of surviving
A172-L treated animals displayed significantly fewer CFU
compared to the kidneys of the control mice at the time of
death (Table 1, experiment 1).
Figure 5. Phage M
SA is inhibited by N-acetyl-glucosamine (GlcNAc), the teichoic acid from A170 (A170
TA) or by treatment with N-
acetyl-glucosaminidase (GlcNA-ase) from Canavalia ensiformis; phage M
SA is not inhibited by the teichoic acid from A172 (A172
TA)o r
glucose. (A) GlcNAc inhibits the lysis of the A170 strain by the phage M
Sa, while glucose (B) does not. (C) A170
TA inhibits the lysis of the A170 strain
by the phage M
SA, while A172
TA does not. (D) The phage-sensitive strain A170 grows in the presence of the M
Sa phage, if pre-treated with GlcAc-ase
(4 U/tube; 2 h at 37uC).
doi:10.1371/journal.pone.0011720.g005
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elicited by a sublethal infection with live S. aureus, mice were
infected with a sublethal dose of A170 and two weeks later
challenged with a lethal dose of A170. There was no significant
difference in surviving between immunized and control mice (P: 1;
Table 1, experiment 2). Thus, the protective response described
above is to be ascribed specifically to A172.
Being a live vaccine, A172 poses the risk of reverting to the
virulent phenotype. This risk is remote (see the section ‘‘Isolation
and morphological characterization of A172’’), albeit considerable
when the use of a large number of vaccine doses is prospected.
The study therefore explored whether A172 remained protective
once it was heat-killed (15 min at 100uC). Mice were vaccinated
with heat-killed vaccine (A172-HK) and 2 weeks later infected
with a lethal dose of A170. The vaccine was protective also in this
form (P: 0.004; Table 1, experiment 3).
When the interval between vaccination and challenge was
extended to 20 weeks, control mice all died within 4 days (10/10);
the vaccinated mice (37/40) were alive 14 days after challenge (P:
0.004; Table 1, experiment 4). Thus, the protection provided by
the vaccine lasts at least 20 weeks.
One more experiment was designed to ascertain whether also
A170 - in the heat-killed form (A170-HK; 15 min at 100uC)- was
protective. No significant difference in survival between immu-
nized and control mice was observed (P: 1; Table 2, experiment 5).
Additional properties of the A172 vaccine
The efficacy of the A172-HK vaccine was tested against two
methicillin-resistant S. aureus (MRSA) (A174 and A175) and one
vancomycin-intermediate S. aureus (VISA) (A176) isolates derived
from patients with staphylococcal infections. Three groups of mice
were immunized with A172-HK and 20 weeks later infected with a
lethal dose of the A174, A175 or A176 isolates. The difference in
survival between vaccinated and control mice was statistically
significant in each case (P: 0.01–0.02; Table 2).
Patients with cystic fibrosis are highly susceptible to S. aureus
lung infection [30]. S. aureus is also one of the most common
causes of pneumonia in paediatric and adult populations [31].
The study therefore explored the efficacy of A172-HK against
lung infections. Mice were immunized by aerosol with A172-HK
and 20 weeks later infected with A170 by the same route. The
vaccine was also effective when administered by aerosol (P: 0.004;
Table 3).
Collectively, the experiments described in this and the preceding
section demonstrate that A172-HK protects mice against a lethal
dose of S. aureus; protection correlates with increased survival and
reduced colonization lasting at least 20 weeks and extending into
drug-resistant isolates of S. aureus; the vaccine is effective when
administered, in single dose and without adjuvant, by the
intramuscular or aerosol routes.
Anti-A172 antibodies protect against S. aureus A170
infection in vivo
Two groups of mice (control mice) were injected intramus-
cularly with normal mouse serum (10 mlo r2 0ml diluted 1:10
with sterile saline, respectively). Two more groups of mice were
treated intramuscularly with serum from mice immunized with
A172-HK (10 mlo r2 0 ml diluted 1:10 with sterile saline,
Figure 6. Gas chromatography-combined mass spectrometry spectra of the teichoic acids from the A170 and A172 strains.
Acetylated O-methyl glycosides from the phage–sensitive A170 and phage-resistant A172 strains of S. aureus. Loss of ribitol (A) and t-GlcNAc linked to
ribitol (B) in the teichoic acids is part of the strategy adopted by A172 to gain phage-resistance. The peak of 4-GlcNAc was chosen as reference. Gro:
glycerol; GlcNAc: N-acetylglucosamine; ManN: N-acetylmannosamine; MurNAc: N-acetyl muramic acid; Glc: glucose; C15:0: pentadecanoic acid; C16:0:
esadecanoic acid; C18:0: octadecanoic acid; C20:0: eicosanoic acid; 4-GlcNAc: 4-linked N-acetylglucosamine; 3GlcAcNMaN: 3-linked N-
acetylmannosamine; t-GlcNAc: terminal GlcNAc.
doi:10.1371/journal.pone.0011720.g006
Table 1. Active protection of A172 in mice challenged with S. aureus strain A170.
Vaccination
Interval vaccination
challenge (weeks) Challenge
Exp
Dose CFU/
mouse Vaccine Route
Dose CFU/
mouse Pathogen Route Survival P value
b
CFU/g
a
(mean ± SD)
11 0
8 A172-L
c Im
d 21 0
8 A170 Im 18/20 0.008 266611
e
- - - 0/10 5.6610
863.5610
8
25 610
6 A170 - 2 10
8 A170 Im 0/10 1 5.7610
863.2610
8
- - - 0/10 5.2610
861.5610
8
31 0
8 A172-HK
f -2 1 0
8 A170 Im 19/20 0.004 260625
e
- - - 0/10 3.5610
861.8610
8
41 0
8 A172-HK - 20 10
8 A170 Im 37/40 0.004 200611
e
- - - 0/10 5.7610
863.3610
8
51 0
8 A170-HK - 2 10
8 A170 Im 0/10 1 5.2610
861.8610
8
- - - 0/10 4.7610
862.3610
8
aColony forming units per g of kidneys (experiments 1–4) or lungs (experiment 5); values calculated on 3 mice.
bTwo tailed Fisher’s exact test.
cA172 Live.
dIntramuscular.
eP,0.001.
fHeat killed A172.
doi:10.1371/journal.pone.0011720.t001
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1:8000. The next day, the mice were all challenged with a lethal
dose of S. aureus A170. Survival was monitored for seven days.
In two independent experiments, the antibodies against A172-
HK - given at the dose of 10 ml/mouse - provided protection to
all the mice (10/10) (P 0.01;Table 4, experiments 1 and 2).
I n s t e a d ,t h es a m es e r u m-g i v e na tt h ed o s eo f2 0ml/mouse -
killed 40%–50% of the mice (P 0.05–0.06; Table 4, experiments
1 and 2). Thus, anti-A172 antibodies can be protective or
detrimental, depending upon the dose being given. This
phenomenon has been described since the development of
serum therapy [32]. In mouse models of Streptococcus pneumoniae
[32] and Cryptococcus neoformans [33], antibody-mediated pro-
tection was also observed within a narrow dose range. Since the
therapeutic use of antibodies in humans is sometimes associated
with myocardial damage [34,35], mice passively immunized
with antibodies against A172-HK were tested for evidence of
heart damage by measuring the level of the cardiac troponin T
i nt h es e r u m .T h i sm a r k e ri sh i g h l ys p e c i f i cf o rm y o c a r d i a l
damage [34]. Mice treated with 20 ml antibodies, compared to
those treated with 10 ml, displayed a statistically significant
higher level of serum troponin T (0.0960.01 ng/ml vs
0.0260.01 ng/ml; P: 0.001). It was not investigated whether
heart damage was the primary cause of death or a secondary
complication of antibody administration. Mice treated with
10 mlo r2 0 ml antibodies displayed both significantly fewer
CFU compared to the mice treated with normal mouse serum
(Table 4, experiments 1 and 2).
In an independent experiment, mice were immunized with
10 ml of anti-A172 mouse serum absorbed with rat anti total
mouse immunoglobulin fraction (5–10 ml) and diluted to 100 ml
with sterile saline. The next day, the mice were challenged with a
lethal dose of S. aureus A170. Absorption of anti-A172 mouse
serum completely eliminated the protective effect of the serum
(Table 4, experiments 3). Collectively, the above results demon-
strate that the passive protection shown by the antibodies against
A172-HK is dose dependent and specific (residing in the antibody
fraction of the serum).
The A172 strain controls inflammation
Ten mice were immunized intramuscularly with A172-HK (10
8
CFU/mouse). A172 modulated transcription of the genes coding
for the pro-inflammatory cytokines TNF-a, IFN-c and IL-1b,
while inducing that of the genes coding for the anti-inflammatory
cytokines Il-4 and Il-6, when these genes were analyzed by RT-
PCR, 24 and 48 h after immunization (Figure 7). The same
pattern of cytokine production was observed in mice immunized
with A172-HK and 20 weeks later infected with A170 (data not
shown). Given the abundant release of pro-inflammatory cytokines
during S. aureus infection [36–37], this property of A172 is
biologically relevant.
Table 2. Protection of heat killed vaccine A172 against drug-resistant S. aureus strains.
Vaccination
Interval vaccination
challenge (weeks) Challenge
Dose
(CFU/mouse) Vaccine Route
Dose
(CFU/mouse) Pathogen Route Survival P value
b
CFU/g
a
(mean ± SD)
10
8 A172-HK
c Im
d 20 10
8 A174 Im 8/10 0.02 250622
e
- - - 0/10 6.7610
861.8610
8
10
8 A172-HK
- 20 10
8 A175 Im 9/10 0.01 330637
e
- - - 0/10 5.8610
861610
8
10
8 A172-HK
- 20 10
8 A176 Im 9/10 0.01 380626
e
- - - 0/10 5.5610
863.6610
8
aColony forming units per g of kidneys; values calculated on 3 mice.
bTwo tailed Fisher’s exact test.
cHeat killed A172.
dIntramuscular.
eP,0.001.
doi:10.1371/journal.pone.0011720.t002
Table 3. Protection of heat killed vaccine A172 administered by aerosol.
Vaccination
Interval vaccination
challenge (weeks) Challenge
Dose
(CFU/mouse) Vaccine Route
Dose
(CFU/mouse) Pathogen Route Survival P value
b
CFU/g
a
(mean ± SD)
10
8 A172-HK
c Aer
d 20 10
8 A170 Aer 19/20 0.004 21663
e
- - - 0/10 7.1610
863.1610
8
aColony forming units per g of kidneys; values calculated on 3 mice.
bTwo tailed Fisher’s exact test.
cHeat killed A172.
dAerosol.
eP,0.001.
doi:10.1371/journal.pone.0011720.t003
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vaccine production
T h r e eg r o u p so fm i c ew e r ei m m u n i z e d( 1 0
8 CFU/mouse,
intramuscularly) with the M
Sa1-resistant strain A178 (derived from
the M
Sa1-susceptible isolate A177), M
Sa2-resistant strain A180 (derived
from the M
Sa2-susceptible isolate A179) or M
Sa3-resistant strain A182
(derived from the M
Sa3-susceptible isolate A181), respectively. Two
weeks later, immunized and control mice were challenged with A170
(10
8 CFU, intramuscularly). The phage-resistant strains all provided
protection in terms of survival and level of host colonization (Table 5;
P: 0.01–0.02) and – like A172 - all lost t-GlcNAc (data not shown) while
all gained the capacity to secrete capsular polysaccharide (Figure 3).
The experiment demonstrates the general applicability of selection for
phage resistance as a means to curb bacterial virulence. The
experiment demonstrates also how different S. aureus isolates use the
same defence strategy against different phages.
The capsular polysaccharide from A172 provides
protection
Capsular polysaccharide (CP) production is a characteristic
common to the four protective strains (A172, A178, A180, A182)
(Figure 3). In an attempt to identify the protective component of
A172, the CP from this strain (CP-A172) was purified and
analyzed by gas liquid chromatography (GLC). CP-A172 contains
glucose and mannose in the molar ratio of 3:1 and traces (molar
ratio: 0.3) of galactose and GlcN (Figure 8). Immunization of mice
with CP-A172 (25 mg/mouse) or treatment with the serum from
mice immunized with CP-A172 (10 ml diluted 1:10 with sterile
saline/mouse) protected mice against a lethal dose of A170 (P:
0.004; Table 6, experiments 1–2).
Discussion
Several virulence factors of S. aureus are being investigated for
their potential use as vaccines [37–38]. However, in view of the
numerous virulence factors produced by this pathogen [39], it is
unlikely that a single component vaccine might protect against a
multitude of virulence factors. Also, virulence genes often display
high levels of variability, as result of the selection pressure to evade
the immune system of the host [40]. The single antigen may
therefore have limited distribution among clinical isolates or may
not be expressed in vivo. The objective of the present study was to
Table 4. Mouse anti A172-HK antibodies protect mice challenged with S. aureus A170 strain.
Passive vaccination Challenge
Exp Treatment
Dose
(ml/mouse) Route
Dose
(CFU for mouse) Strain Route Survival P value
b
CFU/g
a
(mean ± SD)
1 Normal mouse serum 10 Im
c 10
8 A170 Im 0/10 0.01 5.8610
861610
8d
Anti-A172-HK serum - - - - - 10/10 9067
Normal mouse serum 20 Im 10
8 A170 Im 0/10 0.05 4.7610
862610
7d
Anti-A172-HK serum - - - - - 6/10 5.5610
563.6610
4
2 Normal mouse serum 10 Im 10
8 A170 Im 0/10 0.01 3.5610
862610
8d
Anti-A172-HK serum - - - - - 10/10 7366
Normal mouse serum 20 Im 10
8 A170 Im 0/10 0.06 6.3610
861610
8d
Anti-A172-HK serum -
-- -
- 5/10 2.6610
5610
5
3 Anti-A172-HK serum absorbed
with rat anti-mouse IgG
10 Im 10
8 A170 Im 0/10 5.4610
864.2610
7
aColony forming units per g of kidneys; values calculated on 3 mice.
bTwo tailed Fisher’s exact test.
cIntramuscular.
dP,0.0001.
doi:10.1371/journal.pone.0011720.t004
Figure 7. Anti-inflammatory activity of the A172 vaccine. A172 modulates transcription of the genes coding for pro-inflammatory cytokines
(TNF-a, INF-c and IL-1b) and induces transcription of the genes coding for anti-inflammatory cytokines (Il-4 and Il-6).
doi:10.1371/journal.pone.0011720.g007
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antigens and therefore likely to elicit cross-protection against a
spectrum of pathogenic strains. The attenuated strain (A172)
proved effective as vaccine even when heat-killed. Thus, heat-
killed A172 (A172-HK) possesses the advantages of a multiple
component vaccine, without the problems of safety (reversion to
phage sensitivity and the accompanying virulent phenotype),
distribution and manufacturing of the live vaccines [41].
Phage-resistance often (though not always) occurs at a fitness
cost [6,7]. This trade-off explains why phage-resistant and phage-
sensitive bacteria coexist [42]. Bacterial selection for phage-
resistance was therefore exploited as an approach to isolating an
attenuated strain of S. aureus. The approach had already been used
successfully to produce a vaccine against Salmonella enterica serovar
Paratyphi B [18]. The phage-sensitive strain A170, following
growth in vitro in the presence of the M
Sa phage, yielded the
phage-resistant strain A172. Given their common origin, the two
strains share several properties, but display also crucial differences.
They share the spa-type (t6668), the MLST type (ST 45), the egc
type (egc-4) and part of the genome (Figure 1). At the same time,
A170 and A172 differ in their teichoic acid structure and the
capacity to secrete CP. The teichoic acids of A172 lack the
terminal GlcNAc residues (Figure 6B) that phages often use for
adsorption on the cell wall of S. aureus [28]. More importantly,
GlcNAc and the teichoic acids from A170 (A170
TA) inhibit lysis by
the M
Sa phage, while glucose or the teichoic acids from A172
(A172
TA) do not (Figure 5C). These results suggest that A172
gained phage-resistance by losing the phage adsorption site
(terminal GlcNA). However, A172 also displays CP production,
a strategy that some bacteria put in action to mask their phage
adsorption site [43]. In conclusion, while teichoic acid alteration is
the likely mechanism adopted by A172 to gain phage resistance,
the contribution of CP production cannot be excluded.
In a mouse model of infection, A172-HK elicited high levels of
protection against lethal doses of the A170 strain (P 0.004; Table 1,
experiment 3). A single dose of A172-HK, without use of adjuvant,
was fully protective after vaccine administration by the intramus-
cular or aerosol routes and protection lasted at least 20 weeks
(Tables 1–3). Significantly, A172-HK was effective against
methicillin- resistant (MRSA) or vancomycin-intermediate clinical
isolates of S aureus (VISA) (Table 2). Sometime cross-protection has
been attributed to the persistence of the vaccine strain within the
host [44]. This possibility can be excluded in the present study
since the vaccine persists in the immunized animals for only 8
Table 5. Selection for phage-resistance as a general approach for S. aureus vaccine production.
Vaccination
Interval vaccination-challenge
(weeks) Challenge
Dose
(CFU/mouse) Strain Route
Dose
(CFU/mouse) Strain Route Survival P value
b
CFU/g
a
(mean ± SD)
10
8 A178 Im 20 10
8 A177 Im 9/10 0.01 230640
c
- - - - 0/10 4.6610
861.5610
8
10
8 A180 - 20 10
8 A179 Im 10/10 0.01 160634
c
- - - - 0/10 5.3610
862610
8
10
8 A182 - 20 10
8 A181 Im 8/10 0.02 180625
c
- - - - 0/10 3.5610
861.2610
8
aColony forming units per g of kidneys; value calculated on 3 mice.
bTwo tailed Fisher’s exact test.
cP,0.001.
doi:10.1371/journal.pone.0011720.t005
Figure 8. Gas liquid chromatography profile of monosaccharides obtained by acid hydrolysis of the capsular polysaccharide from
S. aureus A172. Abundance expresses the relative ratio between monosaccharides.
doi:10.1371/journal.pone.0011720.g008
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after vaccine administration (Table 1).
Passive immunization of mice with sera from A172-HK
vaccinated mice provided protection against the challenge with a
lethal dose of S. aureus A170. In two independent experiments, 10/
10 of the animals passively immunized with an individual dose of
10 ml immune serum (diluted 1:10 with sterile saline) survived,
while 10/10 untreated control mice died (P: 0.01; Table 4,
experiment 1). When the experiment was repeated using a higher
dose (20 ml immune serum diluted 1:10 with sterile saline/mouse),
40%–50% of the animals died (Table 5, experiment 2). These
results indicate that high antibody doses can be detrimental. This
possibility must be considered when interpreting passive protection
experiments.
A172-HK was protective in vivo, while A170-HK was not
(Table 1). This suggested that A172, along with the resistance to
the M
Sa phage, also acquired the capacity to express a new
molecule, that acts as a protective antigen. Also, the phage-
resistant strains (A172, A178, A180, A182) all display the
characteristic of secreting CP (Figure 3). CPs are heat stable and
can confer protection [45–46]. Taken together, these facts
provided sufficient ground to claim that the protective efficacy of
A172 could reside in its CP (CP-A172). The results confirmed that
CP-A172 provides mice with both active and passive resistance
against a lethal dose of A170 (Table 6). The main components of
CP-A172 are mannose and glucose (Figure 8). This feature
distinguishes CP-A172 from the poly-N-succinyl b-1-6 glucos-
amine vaccine described by McKenney [45] and the capsular
polysaccharide vaccine, that has acetylated fucosamine and
mannosamine as major components [46].
When compared with A170 infected mice, A172-HK vaccinat-
ed animals displayed an elevated transcription level of IL-6
(Figure 7). IL-6 is an anti-inflammatory cytokine controlling
the expression of pro-inflammatory cytokines (IFN-c, I1-b and
TNF-a) [36–38]. Staphylococcal infections cause a profound
release of proinflammatory cytokines, which enhance endothelial
cell permeability and extravasation of bacteria from blood to the
tissues [38]. In particular, elevated levels of IFN-c cause necrosis in
the kidneys of S. aureus-infected mice [37]. Thus, the A172 vaccine,
inducing a balanced pro- and anti-inflammatory response, tempers
the detrimental effects of an excessive inflammation.
It is not uncommon for clinical isolates to be resistant to
staphylococcal phages. This finding deserves a final comment.
Resistant bacteria, despite of their reduced fitness, sometimes
persist because they attenuate the impact of phages on sensitive
bacteria and thus contribute to maintain diversity within the
bacterial population [47].
In conclusion, given the multiple virulence factors expressed by
S. aureus, a whole cell bacterial vaccine would have significant
potential. However, the application of these vaccines (against S.
aureus and bacterial pathogens in general) is limited by the difficulty
of developing reliable procedures of bacterial attenuation [41].
Selection for phage resistance promises to serve this purpose well.
Of course, it must be recalled that the trade-off associated with
phage resistance can be paid by the pathogen in a form other than
lowered virulence. With these caveats, the evidence so far available
– [18] and this article - suggests that selection for phage resistance
as a means to curb bacterial virulence is not particular to the
phage M
Sa or the bacterial strain A172, but more general. Phage
resistance, long considered a problem in the fight against bacteria
[48], is shown here to be an opportunity.
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